CV:ACST Acasti Pharma Inc.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol ACST.

This company has cross-listed shares that trade in the U.S. as the symbol ACST.

0.57 CAD
As of 03/23/2023

---

Security Information

---

Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  01/01/1900
Stock exchange:    TSX Venture Exchange
Exchange country:   Canada
Market cap:   53,588,724 CAD
Current dividend yield:   0.00%
Sedol: